Showing results for:
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Inrebic® Fedratinib
Filgrastim is FDA approved to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with feverReduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresisReduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropeniaIncrease survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
Neupogen® Filgrastim G-CSF Zarxio™ * Filgrastim-sndz* Nivestym™ * Filgrastim-aafi* Releuko* Filgrastim-ayow*
Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:Patients with cancer receiving myelosuppressive chemotherapy;Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;Patients with cancer undergoing bone marrow transplantation;Patients undergoing autologous peripheral blood progenitor cell collection and therapy; andPatients with severe chronic neutropenia.
Zarxio® Filgrastim-sndz
Fludarabine is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) who have not responded to at least one standard alkylting-agent-containing regimen or whose disease has progressed during treatment with such a regimen. This medicine may rarely cause a temporary loss of hair. After treatment with fludarabine has ended, normal hair growth should return.
Fludara® Fludarabine
Leucovorin is an FDA-approved drug similar to the vitamin folic acid. It protects healthy cells from the effects of methotrexate while allowing methotrexate to enter and kill cancer cells.Levoleucovorin (Fusilev®) is a form of leucovorin that is given intravenously (IV).
Folinic acid Leucovorin Levoleucovorin Fusilev®
Panobinostat (Farydak) is FDA approved for the treatment of patients with myeloma who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent. Panobinostat is to be used in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication.
Farydak® Panobinostat
Pegfilgrastim is FDA approved toDecrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).Limitations of Use: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation
Neulasta® Pegfilgrastim G-CSF Fulphila™ * Pegfilgrastim-jmdb* Udenyca™ * Pegfilgrastim-cbqv* Ziextenzo™ * Pegfilgrastim-bmez * Nyvepria Pegfilgrastim-apgf* Fylnetra* Pegfilgrastim-pbbk* Stimufend®* Pegfilgrastim-fpgk*
Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.
Folotyn® Pralatrexate